AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Merus BV (NASDAQ:MRUS)
52.45 USD
-0.655 1.233%| Previous Close (in USD) | 53.105 |
|---|---|
| Change | -0.655 1.233% |
| 52 W H/L (in USD) | 61.610/19.805 |
| EBITDA (in USD) | -164.045M |
| PE Ratio | -- |
| Volume | 431174 |
| Diluted Eps TTM | -2.73 |
| Total Assets (in USD) | 458.494M |
|---|---|
| Total Liabilities (in USD) | 102.151M |
| Revenue TTM (in USD) | 38.337M |
| Cash (in USD) | 205.046M |
| Market Cap (in USD) | 3,199.648 M |
| Revenue Per Share TTM | 0.703 |
| Gross Profit TTM (in USD) | -107.838M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Employees: 172
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Sven Ante Lundberg M.D. | CEO, Pres, Principal Financial Officer & Exec. Director | 1963 |
| 2. | Mr. Peter B. Silverman J.D. | Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal | 1978 |
| 3. | Mr. Hui Liu Ph.D. | Chief Bus. Officer, Exec. VP & Head of Merus U.S. | 1967 |
| 4. | Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor | NA |
| 5. | Harry Shuman | Chief Accounting Officer | NA |
| 6. | Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Exec. VP | 1965 |
| 7. | Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Sr. VP | NA |
| 8. | Ms. Jillian Connell | VP of Investor Relations & Corp. Communications | NA |
| 9. | Mr. Alexander Berthold Hendrik Bakker Ph.D. | Chief Devel. Officer & Exec. VP | 1967 |
| 10. | Dr. Andrew Joe M.D. | Chief Medical Officer & Sr. VP | 1967 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-4.440 6.019% | 68.87 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.570 0.767% | 73 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+0.950 0.216% | 441.69 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.510 0.100% | 510 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -151.747M | -130.235M | -66.577M | -85.01M | -54.957M |
| Minority Interest | - | - | - | - | - |
| Net Income | -154.939M | -131.194M | -66.816M | -85.513M | -55.151M |
| Selling General Administrative | 59.836M | 52.2M | 40.896M | 35.781M | 34.11M |
| Gross Profit | -83.461M | 29.604M | -37.16M | -27.392M | -18.506M |
| Reconciled Depreciation | 2.234M | 1.285M | 1.485M | 1.444M | 1.138M |
| Ebit | -156.547M | -160.038M | -89.976M | -75.878M | -58.657M |
| Ebitda | -154.007M | -184.775M | -113.154M | -65.002M | -60.272M |
| Depreciation And Amortization | 2.54M | -24.737M | -23.178M | 10.876M | -1.615M |
| Operating Income | -156.547M | -160.038M | -89.976M | -75.878M | -58.657M |
| Other Operating Expenses | 200.494M | 201.624M | 139.083M | 105.821M | 89.79M |
| Interest Expense | 14.51M | 2.722M | 0.129M | 18.564M | 6.453M |
| Tax Provision | 2.542M | 0.959M | 0.239M | 0.503M | 0.194M |
| Interest Income | - | 2.722M | - | 0.3M | 1.889M |
| Net Interest Income | 10.746M | 2.722M | -0.129M | 0.3M | 1.889M |
| Income Tax Expense | 3.192M | 0.959M | 0.239M | 0.503M | 0.194M |
| Total Revenue | 43.947M | 41.586M | 49.107M | 29.943M | 31.133M |
| Total Operating Expenses | 197.954M | 201.624M | 139.083M | 105.821M | 89.79M |
| Cost Of Revenue | 127.408M | 11.982M | 86.267M | 57.335M | 49.639M |
| Total Other Income Expense Net | 4.8M | 29.803M | 23.399M | -9.132M | 3.7M |
| Net Income From Continuing Ops | -176.758M | -131.194M | -66.816M | -85.513M | -55.151M |
| Net Income Applicable To Common Shares | - | -131.194M | -66.816M | -85.513M | -55.151M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 458.494M | 376.542M | 456.6M | 231.217M | 263.376M |
| Intangible Assets | 1.8M | 1.95M | 2.347M | 2.843M | 2.876M |
| Other Current Assets | 9.657M | 2.204M | 2.175M | 1.058M | 4.951M |
| Total Liab | 102.151M | 129.487M | 140.399M | 128.954M | 132.076M |
| Total Stockholder Equity | 356.343M | 247.055M | 316.201M | 102.263M | 131.3M |
| Other Current Liab | 40.128M | 37.99M | 22.506M | 22.009M | 13.536M |
| Common Stock | 5.883M | 4.751M | 4.481M | 3.211M | 2.918M |
| Capital Stock | 5.883M | 4.751M | 4.481M | 3.211M | 2.918M |
| Retained Earnings | -753.061M | -598.122M | -466.928M | -400.112M | -314.599M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 6.852M | 2.495M | 2.359M | 2.193M |
| Cash | 205.046M | 147.749M | 241.435M | 163.082M | 197.612M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 69.089M | 78.926M | 71.898M | 46.746M | 36.787M |
| Current Deferred Revenue | 22.685M | 29.418M | 34.661M | 20.179M | 18.842M |
| Net Debt | -192.884M | -134.275M | -237.684M | -159.129M | -192.36M |
| Short Term Debt | 1.674M | 1.684M | 1.494M | 1.432M | 1.38M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 12.162M | 13.474M | 3.751M | 3.953M | 5.252M |
| Other Stockholder Equity | 1126.054M | 870.874M | 787.869M | 490.093M | 441.395M |
| Property Plant Equipment | - | 24.84M | 7.282M | 8.022M | 8.93M |
| Total Current Assets | 368.814M | 306.443M | 424.179M | 217.993M | 247.368M |
| Long Term Investments | 57.312M | 36.457M | 20.297M | 0M | 2.009M |
| Short Term Investments | 150.13M | 142.48M | 168.99M | 44.673M | 42.153M |
| Net Receivables | 3.981M | 4.698M | 6.673M | 1.749M | 2.652M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 0M | 9.312M | 4.906M | 7.431M | - |
| Accounts Payable | 4.602M | 9.834M | 13.237M | 3.126M | 3.029M |
| Accumulated Other Comprehensive Income | -22.533M | -30.448M | -9.221M | 9.071M | 1.586M |
| Non Currrent Assets Other | 2.872M | 4.811M | 2.078M | 1.949M | 1.905M |
| Non Current Assets Total | 89.68M | 70.099M | 32.421M | 13.224M | 16.008M |
| Capital Lease Obligations | 12.162M | 13.474M | 3.751M | 3.953M | 5.252M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -24.047M | 2.802M | -146.623M | -1.486M | 26.77M |
| Total Cashflows From Investing Activities | - | 2.802M | -146.623M | -1.486M | 24.172M |
| Total Cash From Financing Activities | 230.086M | 58.739M | 281.955M | 39.52M | 74.232M |
| Net Income | -154.939M | -131.194M | -66.816M | -85.513M | -55.151M |
| Change In Cash | 56.597M | -93.31M | 78.466M | -34.53M | 33.083M |
| Begin Period Cash Flow | 148.449M | 241.749M | 163.283M | 197.813M | 164.73M |
| End Period Cash Flow | 205.046M | 148.439M | 241.749M | 163.283M | 197.813M |
| Total Cash From Operating Activities | -142.207M | -149.899M | -59.627M | -79.901M | -63.048M |
| Depreciation | 2.54M | 1.285M | 1.485M | 1.444M | 1.138M |
| Other Cashflows From Investing Activities | - | - | - | - | 26.77M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | 1.035M | 4.128M | 2.288M |
| Sale Purchase Of Stock | - | - | -0.285M | - | 74.232M |
| Other Cashflows From Financing Activities | -0.445M | 0.999M | 17.133M | 1.448M | 0.048M |
| Capital Expenditures | 3.982M | 7.639M | 0.87M | 1.287M | 2.598M |
| Change In Working Capital | -25.753M | -18.966M | 15.873M | -14.079M | -15.181M |
| Other Non Cash Items | 8.877M | -23.935M | -27.253M | 8.997M | -1.599M |
| Free Cash Flow | -146.189M | -157.538M | -60.497M | -81.188M | -65.646M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Federated Hermes Kaufmann Small Cap A | 1 year ago | 1475000 |
| 2. | Federated Hermes Kaufmann Small Cap Grow | 1 year ago | 1475000 |
| 3. | Fidelity Select Biotechnology | 1 year ago | 1298015 |
| 4. | Franklin Biotechnology Discv A(acc)USD | 1 year ago | 928380 |
| 5. | Pictet-Biotech P USD | 1 year ago | 761750 |
| 6. | Federated Hermes Kaufmann R | 1 year ago | 755000 |
| 7. | Federated Hermes Kaufmann Growth | 1 year ago | 755000 |
| 8. | HBM Healthcare Investments AG Ord | 1 year ago | 748203 |
| 9. | Franklin Small Cap Growth Adv | 1 year ago | 509900 |
| 10. | Franklin Biotechnology Discovery A | 1 year ago | 499698 |
| 11. | Pictet-Global Megatrend Sel I USD | 1 year ago | 496362 |
| 12. | Franklin Small Cap Growth SMA | 1 year ago | 402200 |
| 13. | Franklin US Small Cap Growth Equity | 1 year ago | 402200 |
| 14. | BlackRock Health Sciences Term Trust | 1 year ago | 384472 |
| 15. | iShares Biotechnology ETF | 1 year ago | 321269 |
| 16. | BlackRock Health Sciences Opps Inv A | 1 year ago | 314737 |
| 17. | Wellington Global Hlthcr Eq USD G Ac | 1 year ago | 257986 |
| 18. | MEDICAL BioHealth EUR Acc | 1 year ago | 231645 |
| 19. | Candriam Global Equities Oncology | 1 year ago | 213000 |
| 20. | Heptagon Driehaus US Micro Cap Eq C$ Acc | 1 year ago | 203356 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | COMMODORE CAPITAL LP | 1 year ago | 4747373 |
| 2. | RTW INVESTMENTS, LLC | 1 year ago | 4109393 |
| 3. | Federated Hermes Inc | 1 year ago | 2248800 |
| 4. | Samlyn Capital, LLC | 1 year ago | 2076590 |
| 5. | Wellington Management Company LLP | 1 year ago | 2009403 |
| 6. | Boxer Capital LLC | 1 year ago | 1900000 |
| 7. | Franklin Resources Inc | 1 year ago | 1883091 |
| 8. | Medicxi Ventures Management (Jersey) Ltd | 1 year ago | 1600000 |
| 9. | BlackRock Inc | 1 year ago | 1429893 |
| 10. | Driehaus Capital Management LLC | 1 year ago | 1226491 |
| 11. | T. Rowe Price Associates, Inc. | 1 year ago | 1185354 |
| 12. | Bvf Inc | 1 year ago | 1172249 |
| 13. | Rock Springs Capital Management LP | 1 year ago | 1146560 |
| 14. | Holocene Advisors, LP | 1 year ago | 939576 |
| 15. | venBio Select Advisor LLC | 1 year ago | 888888 |
| 16. | Goldman Sachs Group Inc | 1 year ago | 773888 |
| 17. | FMR Inc | 1 year ago | 730453 |
| 18. | T. Rowe Price Investment Management,Inc. | 1 year ago | 729015 |
| 19. | Two Sigma Advisers, LLC | 1 year ago | 718500 |
| 20. | Fairmount Funds Management LLC | 1 year ago | 717254 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...